文献速递细胞病理与分子病理

甲状腺细胞学AUS诊断的分子检测与质量保证指标

Molecular testing and other metrics in thyroid cytology as quality-assurance measures in evaluating variation among pathologists in the diagnosis of atypia of undetermined significance.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该研究评估15名细胞病理学认证病理医师的AUS率(7%-44%),并与AUS:M、ROM及Afirma分子阳性率关联,通过散点图和回归分析识别离群指标,结合TBS分类分布解释偏差,提出质量保证框架以标准化诊断阈值。

要点

  • AUS率个体差异大(7%-44%),需结合AUS:M和ROM综合评估。
  • 分子检测阳性率可辅助识别AUS诊断偏差。
  • 反馈TBS分类分布模式有助于标准化诊断阈值。

核心结论

  • AUS率、AUS:M、ROM与分子结果的相关性及TBS分类分布构成稳健的质量保证框架,可揭示与目标基准的偏差及分类间解释偏移。

研究设计与样本

  • 回顾性分析15名细胞病理学认证病理医师的甲状腺细胞学病例,共4801例,其中AUS 926例。
  • 将AUS率与AUS:M、组织学ROM及Afirma分子阳性率进行相关性分析并构建散点图。
  • 比较各病理医师TBS诊断分类分布与实验室平均值,并与上述指标关联。

主要发现

  • 病理医师AUS率范围为7%-44%(均值19%,926/4801例)。
  • 平均AUS:M为7.0%(范围3%-35%),平均ROM为68%(范围25%-87%)。
  • 回归分析识别出离群指标,TBS分类分布分析揭示良性过度诊断为AUS及多分类降级模式。

关键数值与推荐

  • TBS endorsed AUS率≤10%作为可实现目标。
  • AUS:M平均值7.0%,范围3%-35%。
  • ROM平均值68%,范围25%-87%。

临床怎么用

  • 利用AUS率、AUS:M、ROM及分子阳性率与实验室均值比较,识别个体病理医师诊断偏差。
  • 通过TBS分类分布反馈,帮助病理医师调整诊断阈值,减少良性过度诊断为AUS及分类降级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypia of undetermined significance (AUS) is a subjective diagnosis with reported interinstitutional rates ranging from 1% to 20%. The Bethesda System for Reporting Thyroid Cytology (TBS) endorsed ≤10% as an achievable target; however, lowering AUS rates without informed, adjusted diagnostic thresholds can compromise the sensitivity of thyroid cytology. The authors conducted this study to identify quality-assurance measures that can assess individual pathologist's metrics compared with laboratory averages and published benchmarks and can provide feedback to pathologists on the causes of discrepancy. METHODS: AUS rates of 15 cytopathology-boarded pathologists were correlated with AUS:malignant ratios (AUS:M), histologic risks of malignancy (ROMs), and Afirma molecular-positive call rates (PCRs), and scatterplots were constructed. The distribution of pathologist TBS diagnostic categories was compared with laboratory averages and correlated with the above metrics. RESULTS: Pathologist AUS rates ranged from 7% to 44% (mean, 19%; 926 of 4801 cases). Average AUS:M and ROM rates were 7.0% and 68% (range, 3%-35% and 25%-87%), respectively. Regression analysis highlighted pathologists' metrics that were outliers. Evaluation of the distribution of individual pathologist's TBS diagnostic categories identified patterns/trends that explained deviations from laboratory averages, including patterns of significant overcalling of benign as AUS and downgrading diagnoses across multiple TBS categories. CONCLUSIONS: Correlation of AUS, AUS:M, and ROM with molecular results, in addition to the distribution of pathologist TBS categories, offer a robust framework for quality assurance that illustrates deviations from target benchmarks, including shifts in interpretations from one TBS category to another. Giving feedback to pathologists regarding their practice patterns can help standardize diagnostic thresholds and meet designated target metrics.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Elsheikh TM, Sheen C, Bell T, et al. Molecular testing and other metrics in thyroid cytology as quality-assurance measures in evaluating variation among pathologists in the diagnosis of atypia of undetermined significance. Cancer Cytopathol. 2026. PMID: 41609234. doi:10.1002/cncy.70074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。